Cerebral ATP-sensitive potassium channels during acute reduction of carotid blood flow.
The ATP-sensitive potassium channels (KATP) are activated either by a decrease in intracellular ATP content or by a lowering of the ATP-ADP ratio such as during stroke. We studied the role of cerebral KATP on arterial pressure during acute reduction of cerebral blood flow in 12-week-old male Wistar rats anesthetized with urethane by recording arterial pressure and heart rate continuously. After bilateral ligation of the common carotid arteries, glibenclamide, a specific blocker of KATP, was injected intracerebroventricularly into the cerebral lateral ventricle. Glibenclamide elicited a sustained vasopressor response in a dose-dependent manner in rats with bilateral carotid artery ligation (10 nmol, +15 +/- 2 mm Hg; 1 nmol, +5 +/- 1 mm Hg, P < .01 versus vehicle), but hemodynamic alterations were barely recorded with glibenclamide in sham-operated control rats. The abdominal sympathetic discharge was not increased significantly enough to explain the pressor mechanism. Similarly, pretreatments with intravenous injections of bunazosin, an alpha 1-adrenoceptor antagonist, did not affect the pressor response of intracerebroventricular glibenclamide. To investigate the vasopressor mechanism further, we measured plasma and pituitary concentrations of arginine vasopressin and determined the effects of vasopressin receptor antagonists. The intracerebroventricular injections of glibenclamide significantly increased the plasma concentration of vasopressin (P < .05) and significantly decreased the pituitary concentration of vasopressin (P < .05) in rats with bilateral carotid artery ligation. Intravenous pretreatment with the vasopressin V1 receptor antagonist OPC-21268 abolished the vasopressor response to intracerebroventricular glibenclamide (+16 +/- 2 versus +1 +/- 1 mm Hg, P < .01).(ABSTRACT TRUNCATED AT 250 WORDS)
Nishimura
M
M
Department of Clinical Laboratory and Medicine, Kyoto Prefectural University of Medicine, Japan.
Takahashi
H
H
Nanbu
A
A
Sakamoto
M
M
Nakanishi
T
T
Yoshimura
M
M
D000255:Adenosine Triphosphate / Q000494:pharmacology*; D000818:Animals; D001127:Arginine Vasopressin / Q000032:analysis / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000502:physiology*; D002339:Carotid Arteries / Q000502:physiology*; D005905:Glyburide / Q000494:pharmacology; D008297:Male; D010880:Piperidines / Q000494:pharmacology; D010902:Pituitary Gland / Q000378:metabolism; D015221:Potassium Channels / Q000502:physiology*; D015363:Quinolones / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012039:Regional Blood Flow
D010880:Piperidines; D015221:Potassium Channels; D015363:Quinolones; D001127:Arginine Vasopressin; C068644:OPC 21268; D000255:Adenosine Triphosphate; D005905:Glyburide